Fig. 1 · Structure

Documents & Downloads

Primidone

Cat. No. A10754 CAS 125-33-7
Primidone is an anticonvulsant. Potentiates GABAA receptor function.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Sodium channel

Primidone Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Primidone from 3 published references. In vitro models include recombinant human active RIPK1.

Primidone In Vitro Studies

In HEKmTRPM3 cells stimulated with pregnenolone sulfate, Primidone was the most potent TRPM3-inhibiting drug compared with activation without an inhibitor (DMSO control), with an IC50 of 0.6 ± 0.15 μM. In HEK293 cells expressing hTRPM3α2-V992M, Primidone decreased basal calcium levels in a concentration-dependent manner, with an IC50 of 2.41 ± 0.74 μM for V992M. Primidone also efficiently inhibited intrinsic kinase activity in a recombinant human active RIPK1 assay using vehicle alone as the control. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Inhibition of PregS-Induced Calcium Signaling

Cell-based study · HEKmTRPM3 cells; n = 8 [1]

HEKmTRPM3 cells were incubated with various concentrations of Primidone and assessed for PregS-induced Ca2+ signaling against activation without an inhibitor (DMSO control). Primidone was the most potent TRPM3-inhibiting drug, with an IC50 of 0.6 ± 0.15 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PregS-induced Ca2+ signalIC50 IC50 of 0.6 ± 0.15 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
various concentrations
Method
incubating HEKmTRPM3 cells with various concentrations of the respective drug
Vehicle
dimethyl sulfoxide (DMSO)
Co-treatment
Other interventions in this design: Pregnenolone sulfate 35 μM. Compound effect isolated by the comparison: Activation without an inhibitor (DMSO control).
Reported limits
Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: Primidone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and methods > 2.1. Stock solutions and drugs (S1, S4); 2. Materials and methods > 2.3. Intracellular Ca2+ analysis in cell suspensions (S12, S14); 3. Results > 3.2. Concentration dependence of drug-induced inhibition of TRPM3-dependent Ca2+ entry and ionic currents (S75, S79); Figure 2. legend (S147, S148)

PregS-induced Ca2+ signal: PregS-induced Ca2+ signal; comparator: Activation without an inhibitor (DMSO control) — 3. Results > 3.2. Concentration dependence of drug-induced inhibition of TRPM3-dependent Ca2+ entry and ionic currents (S75, S79)

Concentration-dependent reduction of basal calcium levels

Cell-based study · HEK293 cells; hTRPM3α2-V992M [2]

HEK293 cells expressing hTRPM3α2-V992M received Primidone by rapid well injection. Primidone decreased basal calcium levels in a concentration-dependent manner, with an IC50 of 2.41 ± 0.74 μM for V992M.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
basal Ca2+ levelsIC50 21°C; V992M: IC50 2.41 ± 0.74 μM[2]

Literature-Reported Treatment Conditions

Method
rapid well injection
Reported limits
Not stated in the sentences used: dose, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: Primidone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results (S12); Materials and methods > Intracellular Ca2+ assay in 96-well plates (S51); Figure 1. legend (S103, S117, S118, S121); Key resources table (T1.r2)

basal Ca2+ levels: basal Ca2+ levels — Results (S12); Figure 1. legend (S118, S121)

Inhibition of recombinant kinase activity

Biochemical assay · Recombinant human active RIPK1 (aa 1-327) [3]

Recombinant human active RIPK1 was pre-incubated with Primidone at 1 mM for 15 min, with vehicle alone as the control. Intrinsic RIPK1 kinase activity during the reaction phase was efficiently inhibited in the presence of Primidone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RIPK1 kinase activityReported result the intrinsic RIPK1 kinase activity during the reaction phase was efficiently inhibited in the presence of primidone[3]

Literature-Reported Treatment Conditions

Treatment concentration
1 mM
Exposure duration
for 15 min
Method
pre-incubated
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Primidone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Kinase activity assay (S46, S48); Results > Primidone is an effective inhibitor of RIPK1 (S187)

RIPK1 kinase activity: RIPK1 kinase activity; comparator: vehicle alone — Materials and methods > Kinase activity assay (S48); Results > Primidone is an effective inhibitor of RIPK1 (S187)

Primidone In Vivo Studies

Male mice undergoing renal IR with bilateral renal pedicle clamping received Primidone in drinking water before ischemia and through reperfusion. Vehicle-treated mice in the IR group had significantly higher plasma urea and creatinine levels than Primidone-treated animals. [3]

Plasma Urea and Creatinine Following Renal Ischemia–Reperfusion

Animal study · 8-week-old C57BL/6JRj male mice; renal IR; n = 8 per group [3]

Male mice undergoing renal IR with bilateral renal pedicle clamping received Primidone in drinking water before ischemia and through reperfusion. Vehicle-treated mice in the IR group had significantly higher plasma urea and creatinine levels than Primidone-treated animals.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
plasma levels of urea (A) and creatinine (B)Reported result the vehicle-treated mice in the IR group had significantly higher plasma levels of urea (A) and creatinine (B) than the primidone-treated animals[3]

Conditions shared by the study groups

Route
drinking water
Treatment course
5 days before the onset of ischemia and until the end of the reperfusion phase
Vehicle
dimethyl sulfoxide (DMSO)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Primidone 2.875 mMvehicle-treated mice in the IR groupthe vehicle-treated mice in the IR group had significantly higher plasma levels of urea (A) and creatinine (B) than the primidone-treated animals[3]
Primidone 2.875 mM
Model: 8-week-old C57BL/6JRj male mice; renal IR; n = 8 per group
Methods and source locations

Compound reported in the paper: Primidone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Mice (S19); Materials and methods > Kidney IRI (S50); Results > Preclinical animal models confirm the efficacy of primidone (S199, S200, S201)

plasma levels of urea (A) and creatinine (B): plasma levels of urea (A) and creatinine (B); comparator: vehicle-treated mice in the IR group — Results > Preclinical animal models confirm the efficacy of primidone (S201)

Primidone 2.875 mM · Results > Preclinical animal models confirm the efficacy of primidone (S200, S201)

Specifications

Manufacturer Adooq Bioscience
CAS Number 125-33-7
Formula C12H14N2O2
Molecular Weight 218.25
Synonyms Neurosyn; Mylepsin; Mysoline
SMILES
CCC1(C(=O)NCNC1=O)C2=CC=CC=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 41 mg/mL (187.85 mM)
Water Insoluble
Ethanol 3 mg/mL (13.74 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Primidone Research References

  1. [1] Krügel U, Straub I, Beckmann H, et al. Primidone inhibits TRPM3 and attenuates thermal nociception in vivo. Pain (2017). PMID: 28106668 DOI: 10.1097/j.pain.0000000000000846 Source material
  2. [2] Zhao S, Yudin Y, Rohacs T. Disease-associated mutations in the human TRPM3 render the channel overactive via two distinct mechanisms. Elife (2020). PMID: 32343227 DOI: 10.7554/eLife.55634 Source material
  3. [3] Riebeling T, Jamal K, Wilson R, et al. Primidone blocks RIPK1-driven cell death and inflammation. Cell Death Differ (2021). PMID: 33273695 DOI: 10.1038/s41418-020-00690-y Source material

Added to your cart

View Cart Checkout
Loading...